RxDoctor Payments DataLook up a doctor →

Alok Gopal, MD

Interventional Pain Medicine · Winchester, VANPI 1174588107

Payments from drug & device makers

$15,575in general payments, 2019–2025

Across 601 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$2K
  • Boston Scientific$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Nevro Corp.$803
  • Biotronik NRO, Inc.$482
  • plus $6K from 43 others

What the payments were for

  • Travel & lodging$1,0497%
  • Food & beverage$14,45793%
  • Education$690%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,575 in reported general payments places this provider in the 85th percentile of 52 interventional pain medicine providers in Virginia.

See all interventional pain medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$478,650
Medicare patients
439
Services billed
6,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate41$24,527
Pregabalin290$7,499
Buprenorphine43$5,924
OxycontinOxycodone Hcl11$5,859
Fentanyl59$4,455
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen236$4,152
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen174$3,170
Morphine Sulfate ErMorphine Sulfate89$2,361
Lidocaine19$2,211
Gabapentin122$1,684
Tramadol Hcl180$1,365
Tizanidine Hcl38$819
Tramadol Hcl ErTramadol Hcl18$788
Methadone Hcl38$598
Diclofenac Sodium48$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$1,058$24,52741 claims
Hikma Pharmaceuticals USABuprenorphine$39$5,92443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 52 interventional pain medicine providers in Virginia.

Other interventional pain medicine in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →